PT-141: bremelanotide, explained

What it is

PT-141, or bremelanotide, is a synthetic cyclic heptapeptide and a melanocortin receptor agonist — it activates several melanocortin receptors, with MC4R the most relevant at therapeutic doses (MC1R, the pigment receptor, accounts for the skin-darkening effect). It's the active metabolite of Melanotan II, developed from α-MSH research. The key mechanistic point: unlike PDE5 inhibitors (Viagra and similar), which act peripherally on the vasculature, PT-141 acts centrally — in hypothalamic/limbic regions where MC4R activation engages sexual-desire pathways. It's a desire drug, not a blood-flow drug.

Approval & what the trials showed

Bremelanotide is FDA-approved as Vyleesi (June 2019) for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women — low sexual desire causing marked distress, not explained by another condition, medication or relationship issue. The approval rests on the two RECONNECT Phase 3 trials (24 weeks, ~1,200+ premenopausal women, 1.75 mg SC as-needed vs placebo), which met their co-primary endpoints: statistically significant improvements in a validated desire score and a reduction in distress.

The honest caveat: the effect size was modest — significant on the scales, but small in absolute terms (for example, roughly a quarter of patients had a meaningful desire increase vs about 17% on placebo). It works for some women with HSDD; it is not a dramatic across-the-board libido switch. Earlier research also studied bremelanotide for erectile dysfunction in men (an intranasal program was halted over blood-pressure concerns), after which development pivoted to the subcutaneous autoinjector for female HSDD.

Side effects — take these seriously

From the Vyleesi label and Phase 3 data, the side-effect profile is well documented and worth stating plainly:

• Nausea — ~40% (very common); it's the leading reason people stop, and some need anti-nausea medication.
• Flushing (~20%), headache (~11%), and injection-site reactions.
• Transient blood-pressure increase with a drop in heart rate — peaking a few hours after dosing. Because of this, Vyleesi is contraindicated in uncontrolled hypertension or known cardiovascular disease.
• Focal hyperpigmentation — darkening of skin, gums or face, more frequent with repeated/frequent dosing (and in lighter-skinned individuals); it may not fully resolve. This is a melanocortin (MC1R) effect.

PT-141 vs Melanotan II

Both are synthetic melanocortin agonists from α-MSH, and they're often confused. Melanotan II is the tanning-focused one — broader/stronger MC1R activation, hence pronounced skin pigmentation — and it's not approved anywhere, sold only gray-market. PT-141/bremelanotide is Melanotan II's active metabolite, developed specifically as a sexual-desire drug (MC4R-predominant central effect), with pigmentation as a side effect rather than the goal — and it is approved, as Vyleesi.

The math

The approved Vyleesi is a pre-filled autoinjector — no reconstitution. The arithmetic only matters for gray-market PT-141, which is sold as lyophilized powder reconstituted with bacteriostatic water and dosed in milligrams — the same math the peptide reconstitution calculator does. Worked example, purely as arithmetic:

Concentration is just milligrams divided by millilitres, and units are just hundredths of a millilitre on a U-100 insulin syringe. The reconstitution calculator converts vial size + water + target into exact syringe units. The milligrams above are illustrative arithmetic, not a recommended dose. PT-141 is dosed on-demand, not daily: the approved schedule is ~45 minutes before activity, max once per 24 hours and 8 doses per month — partly because frequent dosing drives the hyperpigmentation. The elimination half-life is ~2.7 hours.

Storage & handling

• Vyleesi autoinjector: stored per the label; no reconstitution or measuring — it's a fixed 1.75 mg dose.
• Gray-market lyophilized powder: kept cold and away from light; once reconstituted in bacteriostatic water, refrigerated at 2–8°C and used within about four weeks.
• Quality honesty: gray-market PT-141 is unregulated — purity, identity and sterility are not guaranteed, unlike the approved Vyleesi product.

Tracking PT-141 in OptiPin

If you are tracking PT-141, OptiPin treats it as an on-demand entry:

• On-demand dose log — record each use (with the timing before activity) rather than a daily schedule, and keep a running count toward the monthly limit that matters for pigmentation risk.
• Side-effect & blood-pressure notes — log nausea, flushing and any BP readings over your dose timeline — the monitoring that actually matters for this compound.
• OptiInsight analysis — OptiPin's AI reads the full record (doses, symptoms, labs) and surfaces what moved with what.
• Supply tracking — log the autoinjector count or reconstituted vial; OptiPin estimates remaining doses and an empty date.
• Built-in reconstitution math — for a measured gray-market dose, the same calculator covered above is one tap in the app.